1. DRUG INNOVATION FUND JOINT ACADEMIC AND RELEVANCE REVIEW PANEL

Members of the Joint Academic and Relevance Review Panel will be chosen by Ontario Public Drug Programs (OPDP) in collaboration with the Chair of the Panel. Candidates will be assessed on their qualifications, track record in their field of study and ability to involve decision-makers in drug program service delivery and policy, based on the evaluation guidelines. The Panel must be viewed as independent and impartial.

Composition of the Peer Review Panel

• The Joint Academic and Relevance Review Panel will consist of up to 11 members (five academic reviewers, five relevance reviewers, and one Chair). The Chairperson will vote only to break a tie.
• Researchers, decision makers and industry representatives will be represented on the panel.
  The representation may include the following :
• Decision-maker partners (MOHLTC, Ministry of Research and Innovation)
• Industry representatives
• Service provider
• Researchers from across the province
• Patient group representative, preferably from patient group involved in research
• A Chairperson shall be selected, and shall assist with the recruitment of Panel members.

Filling vacancies

• Members are asked to inform the Chair and OPDP at least three months prior to exiting the Panel.
• The original nominating organization is responsible for identifying a suitable replacement.

See also :

• Review Panel Members' Responsibilities
• Terms and Procedures
• The Review Process
• Reporting on Progress
• Chair Responsibilities